Back to search

France· FR:64336907

EVKEEZA 150 mg/ml, solution à diluer pour perfusion

A evinacumab product containing évinacumab, registered in France by ULTRAGENYX GERMANY (ALLEMAGNE). The same ATC class is registered in 12 of our 19 countries.

ATC C10AX17

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedEVKEEZA 150 mg/ml, solution à diluer …ATCC10AX17REGISTER NO.FR:64336907PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Evinacumab is registered in 12 of 19 countries.

Countries holding a registration under ATC C10AX17 (evinacumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Evinacumab · ATC C10AX17

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
ÉVINACUMAB
Manufacturer
ULTRAGENYX GERMANY (ALLEMAGNE)
Country
France (FR)
ATC code
C10AX17
ATC class
Evinacumab
Defined daily dose
37.5 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955089049
    1 flacon(s) en verre de 2,3 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5b5032b0-7716-4396-bf12-a1bc3fe1a76f
GET /v1/drugs/5b5032b0-7716-4396-bf12-a1bc3fe1a76f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64336907",
  "date_amm": "2021-06-17",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/21/1551",
  "substance": "ÉVINACUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about evinacumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.